UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Multicentre phase II study of cisplatin–etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study

Annals of oncology, 2013-06, Vol.24 (6), p.1548-1552

2013

Volltextzugriff (PDF)

Clinical benefit of anti PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment in advanced non-small cell lung cancer: A meta-analysis

Annals of oncology, 2019-04, Vol.30, p.ii60-ii60

2019

Volltextzugriff (PDF)

IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC

Annals of oncology, 2019-10, Vol.30, p.v915

2019

Volltextzugriff (PDF)

Patients with non-small-cell lung cancer harbouring a BRAF mutation: a multicentre study exploring clinical characteristics, management, and outcomes in a real-life setting: EXPLORE GFPC 02-14

Current oncology (Toronto), 2018-10, Vol.25 (5), p.e398-402

2018

Volltextzugriff (PDF)

Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)

BMC cancer, 2015-11, Vol.15 (858), p.857-857, Article 857

2015

Volltextzugriff (PDF)

Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study

Lung cancer (Amsterdam, Netherlands), 2014-09, Vol.85 (3), p.415-419

2014

Volltextzugriff (PDF)

A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study)

British journal of cancer, 2011-10, Vol.105 (8), p.1123-1130

2011

Volltextzugriff (PDF)

Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study

Current medical research and opinion, 2014-03, Vol.30 (3), p.447-461

2014

Volltextzugriff (PDF)

A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis

Kidney international, 2022-02, Vol.101 (2), p.390-402

2022

Volltextzugriff (PDF)

A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0505 study)

Lung cancer (Amsterdam, Netherlands), 2012-07, Vol.77 (1), p.97-103

2012

Volltextzugriff (PDF)

Geriatric assessment contribution to treatment decision-making in thoracic oncology

Revue des maladies respiratoires, 2011-11, Vol.28 (9), p.1124

2011

Volltextzugriff (PDF)

Impact of chronic airflow obstruction in a working population

The European respiratory journal, 2008-06, Vol.31 (6), p.1227-1233

2008

Volltextzugriff (PDF)

Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study

Targeted oncology, 2016-04, Vol.11 (2), p.167-174

2016

Volltextzugriff (PDF)

Corrigendum to “Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study” [Lung Cancer 85 (2014) 415–419]

Lung cancer (Amsterdam, Netherlands), 2015-02, Vol.87 (2), p.210-210

2015

Volltextzugriff (PDF)

PCN109 Cost Effectiveness of First Line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients: A Markov Model

Value in health, 2011, Vol.14 (7), p.A454-A454

2011

Volltextzugriff (PDF)

9056 POSTER Incidence and Management of Adverse Events (AEs) in Patients Receiving Different Types of Treatment for Non-small Cell Lung Cancer (NSCLC) Across Europe – EPICLIN-Lung Study

European journal of cancer (1990), 2011, Vol.47, p.S608-S608

2011

Volltextzugriff (PDF)

PCN9 From Indirect Evidence to Direct Evidence: A Real-World Example for the Value of Indirect Treatment Comparisons in Second-Line NSCLC Therapy

Value in health, 2012-06, Vol.15 (4), p.A209-A209

2012

Volltextzugriff (PDF)

Simulation and Comparison of Progression-Free Survival (Pfs) Among Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Receiving Sequential Therapy

Value in health, 2014-05, Vol.17 (3), p.A70-A70

2014

Volltextzugriff (PDF)

165PClinical benefit of anti PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment in advanced non-small cell lung cancer: A meta-analysis

Annals of oncology, 2019-04, Vol.30 (Supplement_2)

2019

Volltextzugriff (PDF)

Real-world healthcare resource utilization in a European non-small cell lung cancer population: the EPICLIN-Lung study

Current medical research and opinion, 2014-03, Vol.30 (3), p.463-470

2014

Volltextzugriff (PDF)

The costs of asthma in France and the economic implications of its level of control

Revue des maladies respiratoires, 2011-04, Vol.28 (4), p.419-426

2011

Volltextzugriff (PDF)

Assessment of preoperative noninvasive ventilation before lung cancer surgery: The preOVNI randomized controlled study

The Journal of thoracic and cardiovascular surgery, 2020-10, Vol.160 (4), p.1050-1059.e3

2020

Volltextzugriff (PDF)

9016 POSTER DISCUSSION Erlotinib Vs Chemotherapy (CT) in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients (p) With Epidermal Growth Factor Receptor (EGFR) Activating Mutations – the EURTAC Phase II Randomized Trial Interim Results

European journal of cancer (1990), 2011, Vol.47, p.S597-S597

2011

Volltextzugriff (PDF)

Tools for assessing healthcare delivery

Revue des maladies respiratoires, 2006-02, Vol.23 (1 Suppl), p.3S47-3S60

Vergnenègre, A

2006

Volltextzugriff (PDF)

Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010

Annals of oncology, 2011-07, Vol.22 (7), p.1507-1519

2011

Volltextzugriff (PDF)

1 – 25 von 575

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(531)
Mit Volltextzugriff
(322)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(178)
Science & Technology
(167)
Life Sciences & Biomedicine
(160)
Male
(115)
Female
(103)
Middle Aged
(101)
Aged
(100)
Oncology
(84)
Lung Neoplasms - Drug Therapy
(73)
Respiratory System
(72)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(64)
Adult
(63)
Lung Cancer
(63)
Sciences Biologiques Et Medicales
(62)
Sciences Medicales
(62)
Life Sciences
(52)
Chemotherapy
(48)
Pneumologie
(46)
Lung Neoplasms - Pathology
(45)
Aged, 80 And Over
(44)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Multicentre phase II study of cisplatin–etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study

Clinical benefit of anti PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment in advanced non-small cell lung cancer: A meta-analysis

IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC

Patients with non-small-cell lung cancer harbouring a BRAF mutation: a multicentre study exploring clinical characteristics, management, and outcomes in a real-life setting: EXPLORE GFPC 02-14

Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)

Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study

A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study)

Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study

A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis

A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0505 study)

Geriatric assessment contribution to treatment decision-making in thoracic oncology

Impact of chronic airflow obstruction in a working population

Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study

Corrigendum to “Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study” [Lung Cancer 85 (2014) 415–419]

PCN109 Cost Effectiveness of First Line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients: A Markov Model

9056 POSTER Incidence and Management of Adverse Events (AEs) in Patients Receiving Different Types of Treatment for Non-small Cell Lung Cancer (NSCLC) Across Europe – EPICLIN-Lung Study

PCN9 From Indirect Evidence to Direct Evidence: A Real-World Example for the Value of Indirect Treatment Comparisons in Second-Line NSCLC Therapy

Simulation and Comparison of Progression-Free Survival (Pfs) Among Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Receiving Sequential Therapy

165PClinical benefit of anti PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment in advanced non-small cell lung cancer: A meta-analysis

Real-world healthcare resource utilization in a European non-small cell lung cancer population: the EPICLIN-Lung study

The costs of asthma in France and the economic implications of its level of control

Assessment of preoperative noninvasive ventilation before lung cancer surgery: The preOVNI randomized controlled study

9016 POSTER DISCUSSION Erlotinib Vs Chemotherapy (CT) in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients (p) With Epidermal Growth Factor Receptor (EGFR) Activating Mutations – the EURTAC Phase II Randomized Trial Interim Results

Tools for assessing healthcare delivery

Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010

Suchergebnisse filtern